Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis

Rashid Alam Mahumud 1,2,3,* 1, Mohammad Afshar Ali 2,4,5 4, Satyajit Kundu 6,7 6, Md Ashfikur Rahman 8,9, Joseph Kihika Kamara 9,10 and Andre M. N. Renzaho 11,12

Abstract: Objectives: The highly transmissible COVID-19 Delta variant (DV) has contributed to a surge in cases and exacerbated the worldwide public health crisis. Several COVID-19 vaccines play a significant role in a high degree of protection against the DV. The primary purpose of this meta-analysis is to estimate the pooled effectiveness of the COVID-19 vaccines against the DV in terms of risk ratio (RR) among fully vaccinated, compared to unvaccinated populations. Methods: We carried out a systematic review, with meta-analysis of original studies focused on COVID-19 vaccines effectiveness against a DV clinical perspective among fully COVID-19 vaccinated populations, compared to placebo (unvaccinated populations), published between 1 May 2021 and 30 September 2021. Eleven studies containing the data of 17.2 million participants were identified and included in our study. Pooled estimates of COVID-19 vaccines effectiveness (i.e., risk ratio, RR) against the DV with 95% confidence intervals were assessed using random-effect models. Publication bias was assessed using Egger’s regression test and funnel plot to investigate potential sources of heterogeneity and identify any differences in study design. Results: A total population of 17.2 million (17,200,341 people) were screened for the COVID-19 vaccines’ effectiveness against the DV. We found that 61.13% of the study population were fully vaccinated with two doses of COVID-19 vaccines. The weighted pooled incidence of COVID-19 infection was more than double (20.07%) among the unvaccinated population, compared to the fully vaccinated population (8.16%). Overall, the effectiveness of the COVID-19 vaccine against the DV was 85% (RR = 0.15, 95% CI: 0.07–0.31). The effectiveness of COVID-19 vaccines varied slidably by study designs, 87% (RR = 0.13, 95% CI: 0.06–0.30) and 84% (RR = 0.16, 95% CI: 0.02, 1.64) for cohort and case-control studies, respectively. Conclusions: The effectiveness of COVID-19 vaccines were noted to offer higher protection against the DV among vaccinated populations who received two vaccine doses compared with the unvaccinated population. This finding would help efforts to maximise vaccine coverage (i.e., at least 60% to 70% of the population), with two doses among vulnerable populations, in order to have herd immunity to break the chain of transmission and gain greater overall population protection more rapidly.

1 NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia
2 School of Business and Centre for Health Research, University of Southern Queensland, Toowoomba, QLD 4350, Australia; mohammadafshar.ali@usq.edu.au
3 Health Research Group, Department of Statistics, University of Rajshahi, Rajshahi 6205, Bangladesh
4 Allied Health and Human Performance Unit, University of South Australia, Adelaide, SA 5001, Australia
5 Department of Economics, Jagannath University, Dhaka 1100, Bangladesh
6 Faculty of Nutrition and Food Science, Patuakhali Science and Technology University, Patuakhali 8602, Bangladesh; satyajit@seu.edu.cn
7 School of Public Health, Southeast University, Nanjing 21009, China
8 Development Studies Discipline, Khulna University, Khulna 9208, Bangladesh; ashfikur@ku.ac.bd
9 World Vision East Africa Regional Office, Karen Road, Off Ngong Road, Karen, Nairobi 50816, Kenya; joseph.kamara@wvi.org
10 Centre for Humanitarian Leadership, Deakin University, Melbourne, Burwood, VIC 3125, Australia
11 School of Medicine, Translational Health Research Institute, Western Sydney University, Campbelltown, NSW 2150, Australia; andre.renzaho@westernsydney.edu.au
12 Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, VIC 3004, Australia

* Correspondence: rashed.mahumud@sydney.edu.au; Tel.: +61-(2)-95625294

Published: 11 February 2022
Accepted: 9 February 2022
Academic Editor: Sarah R. Leist

Citation: Mahumud, R.A.; Ali, M.A.; Kundu, S.; Rahman, M.A.; Kamara, J.K.; Renzaho, A.M.N. Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis. Vaccines 2022, 10, 277. https://doi.org/10.3390/vaccines10020277

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Keywords: delta variant; COVID-19 vaccines; herd immunity; vaccines effectiveness; meta-analysis; B.1.617.2

1. Introduction
On 19 May 2021, the Delta variant (DV) of concern, formerly known as the Indian variant of concern (or B.1.617.2), became the most dominant strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The SARS-CoV-2 DV that was reported in 185 countries [2] is more contagious, with a higher number of R-naught ($R_0$ of 5–6) compared to other variants (e.g., Alpha, Beta, Gamma) [3]. A significant number of new COVID-19 cases, caused by the highly transmissible DV, is exacerbating the worldwide public health crisis [4]; 99% of sequenced and genotyped cases are related to the DV. The burden of the DV has led to considerable demand for herd immunity and the optimal timing of booster doses for the vaccinated population [5]. Coronavirus disease-19 (COVID-19) vaccines have been identified as the most effective means of halting the spread of the disease over the world. Several vaccines are currently being administered to people of various ages all around the world. Nonetheless, two doses of vaccines have played a significant role in terms of a high degree of protection before the Delta variant than one dose of vaccination [6]. The vaccines’ performance remains significant, but they have yet to lead to herd immunity to break the chain of transmission of the Delta variant [7]. Emerging evidence suggests the BNT162b2 mRNA vaccine (Pfizer-BioNTech) and the Oxford AstraZeneca adenovirus-vector vaccine, ChAdOx1 nCoV-19 (ChAdOx1), exhibit great efficiency against the Alpha (B.1.1.7) variant and other variants before the DV [8–11].

The continued appearance of novel SARS-CoV-2 variations could jeopardise the efficacy of immunisation efforts, especially since in vitro tests suggest that vaccine-elicited antibodies have lower neutralisation activity against emergent variants [12,13]. The DV is of particular concern as it has resulted in substantial increases in infections in many countries, including ones with excellent vaccination coverage, such as the United Kingdom (UK), where it swiftly became dominant after being recognised as a Variant of Concern (VOC) on 28 April 2021 [13].

The rapid pace at which data is emerging, as well as heterogeneities in study protocols and designs, different socioeconomic and demographic characteristics (i.e., age, sex, ethnicity, comorbidities), and regions and implementation, make interpreting and assessing the anticipated impact of vaccine campaigns on local epidemics difficult and challenging. Measuring the effectiveness of COVID-19 vaccines against the most dominant variant (B.1.617.2) can be a basis for accentuating protection in patients with COVID-19 infection. In contrast, there is still a scarcity of real-world data on the effectiveness of vaccines against the DV [14]. Therefore, using a systematic review and meta-analysis, we aim to estimate the pooled COVID-19 vaccines efficacy and effectiveness against the DV. This study is important and, unlike previous systematic reviews and meta-analyses [15–17], which have focused on risk assessment, immunogenicity, reactogenicity and efficacy across different vaccine platforms.

We anticipated that our study findings will provide a comprehensive understanding of the effectiveness of COVID-19 vaccines and will inform strategies to promote protection against COVID-19, especially the DV. Furthermore, the study provides real-time evidence to boost vaccine confidence. Globally, there have been unfounded concerns that have affected public confidence in vaccines and triggered vaccine hesitancy, which could delay the fight against the pandemic if not urgently addressed [18,19].

2. Methods
2.1. Search Strategy
We conducted a comprehensive search for academic research studies that reported the effectiveness of COVID-19 vaccines against the COVID-19 Delta variant, published between 1 May 2021 and 30 September 2021, from the following electronic bibliographic databases:
Scopus, EBSCOhost (CINAHL, Medline), PubMed, Web of Science, and the first 20 pages of Google Scholar. The following search terms were used with no language restrictions:

([“Effectiveness” OR “Efficacy” OR “Security” OR “Safety” OR “Evaluation”) AND (“COVID-19 Vaccines” OR “Coronavirus-19 Vaccines” OR “mDNA COVID-19 vaccines” OR “Moderna” OR “mRNA-1273” OR “Pfizer/BioNTech” OR “BNT162b2” OR “Johnson & Johnson” OR “Ad26.COV2.S” OR “Oxford/AstraZeneca” OR “AZD1222” OR “BBIBP-CorV” OR “Vero Cells” OR “CoronaVac” OR “Vaccines”) AND (“Delta Variant” OR “B.1.617.2” OR “Delta” OR “Alpha Variant” OR “Variant”]).

2.1.1. Study Participants

This meta-analysis study comprises vaccinated or unvaccinated populations that were infected with COVID-19 since the delta variant emerged.

2.1.2. Inclusion and Exclusion Criteria

In this meta-analysis, eligible studies were selected if they (1) were original articles; (2) published between 1 May 2021 and 30 September 2021 (focused on the Delta variant); (3) focused on the effectiveness of COVID-19 vaccines against the DV (B.1.617.2) clinical perspective, (4) effectiveness or efficacy of all COVID-19 vaccines, (5) effectiveness or efficacy on fully COVID-19 (i.e., two-doses) vaccinated people compared to placebo (unvaccinated), and (6) reported clinical characteristics of COVID-19 among infected people. Editorials, letters, perspectives, commentaries, reports, opinion species, reviews, and studies with ‘insufficient related data’ were excluded from the analysis. The reference lists of studies included were checked for eligible studies. We selected the starting date of 1 May 2021 because it marks a period when B.1.617.2 was escalated, the VOC having been earlier detected in April 2021 [13,20].

2.1.3. Data Extraction

Data were independently extracted into EndNote libraries by three researchers who later compared their results. Emerging differences in the data were discussed and resolved by consensus, and, where the three researchers could not agree, the fourth and fifth researchers were consulted for adjudication. The extracted data captured the author’s name, year, settings, design or approach, the overall number of COVID-19 infections, the number of vaccinated and unvaccinated participants, and the number of participants.

2.1.4. Study Screening and Selection

The screening and selection of studies followed a three-stage screening procedure. The first stage involved screening studies by title to eliminate duplicates. The second stage required the reading of abstracts to determine their relevance to our study. The third stage necessitated the reading of full texts of the retained studies from the second stage, and those that met the set criteria were retained for our study, as reflected in Figure 1. R.A.M. carried out and recorded the above process and shared the record with two other authors (M.A.A. and M.A.R.) for verification. Discrepancies were discussed and resolved by consensus.

2.1.5. Quality Assessment

Quality assessment was independently conducted by two authors who applied four quality assessment tools due to the heterogeneity of included studies designs. Discrepancies in the two authors’ quality assessments were referred to the other authors for adjudication. The included studies designs were cohort, case series, and case controls. The three critical appraisal tools applied were from the Joanna Briggs Institute (JBI). The JBI tools have been used widely in academic studies [21,22]. The tools provide a subjective assessment of risk of bias (ranked as low, moderate, or high) [23]. Higher quality indicates greater confidence that future research is unlikely to change or contradict the results, while lower quality indicates a higher likelihood that future research may not affirm the study results. The first JBI tool used was the checklist for cohort studies, which we applied to
four studies [24–27] included in this systematic review and meta-analysis. The checklist assesses critical areas of studies’ methodologies for biasness in design, implementation, and analysis (Appendix A Table A1). The second tool of quality assessment used was the JBI checklist for analytical case–control studies, which we applied to the six case–control studies [6,28–32] included in this review. The checklist consists of 10 items that enable the critical appraisal of studies for potential biasness (Appendix A Table A2). The third and last tool used was the JBI checklist for case series studies, which was applied to one study included [33] in our review (Appendix A Table A3). The checklist comprises of 10 items measuring the comparability of the study groups, the matching of cases and controls, the identification criteria for cases and controls, the reliability and validity of exposure measurement, similarities in exposure measurement for case and control, the identification of confounding factors, addressing the confounding factors, the assessment of outcomes, the length of the exposure period, and statistical analysis.

Figure 1. Steps of study selection procedures.

2.2. Data Analysis

Given the high heterogeneity between studies ($I^2 > 50\%)$ [34], we used random effects meta-analysis models to obtain pooled two-dose COVID-19 vaccines effectiveness (VE) estimates against the Delta variant (B.1.617.2), complemented with a sensitivity analysis to examine the effects of outliers. VE was calculated as 1—risk ratio (RR).

$$\text{VE} = \frac{\text{Risk among unvaccinated group} - \text{Risk among vaccinated group}}{\text{Risk among unvaccinated group}}$$

Alternatively, $\text{VE} = 1 - \text{risk ratio (RR)}$

For two-dose VE, we calculated the pooled estimate of VE against the delta variant and by study design. We assessed residual heterogeneity between studies by calculating the $I^2$ statistic [34]. The $I^2$ statistic enabled us to determine whether the percentage of variance was attributable to the heterogeneity of the data in studies included using the random-effects model. We used forest plots to show the distribution of RR of COVID-19 infection during the delta variant. Subgroup analysis based on the vaccine phases significantly decreased the heterogeneity in the high heterogeneity cases. The presence and effect of publication bias were assessed by using Egger’s regression test [35] and funnel plot [36] to investigate potential sources of heterogeneity and identify any differences in study
design. All analyses, two-tailed statistics and a significance level of less than 0.05 were considered. All statistical analyses were performed by STATA/SE version 15.0 (StataCorp, College Station, TX, USA).

3. Results

3.1. Description of Studies Included

Our primary search of databases yielded 753 studies, of which 11 met the criteria (i.e., six studies were case-control [6,28–32], four studies were cohort design [24–27], and one study was case-case design [33]) and were included in this study (Figure 1). The included studies had a total sample of ~17.2 million (N = 17,200,341) people and, of these, 61.13% of were fully vaccinated (n = 10,514,132) with two-doses of COVID-19 vaccines (Table 1). The COVID-19 infection was more than double (21.61%, 95% CI: 8.50%–34.72%) among the unvaccinated population, compared to the fully vaccinated population (8.88%, 95% CI: 0.18%–17.95%).

Table 1. Characteristics of the selected studies.

| Study               | Country | Design       | Fully Vaccinated Group | Unvaccinated Group |
|---------------------|---------|--------------|------------------------|--------------------|
|                     |         |              | Number of Infected     | Total Vaccinated   |
|                     |         |              | Persons, n (%)         | Population         |
|                     |         |              |                        | Number of Infected |
|                     |         |              |                        | Persons, n (%)     |
|                     |         |              |                        | Total Unvaccinated |
|                     |         |              |                        | Population         |
| Bernal et al. (2021) [30] | UK      | Case–control | 143 (0.60)              | 23,993             |
|                     |         |              | 23,993 (7.59)           | 73,13 (7.59)       |
| Fowlkes et al. (2021) [24] | USA     | Cohort study | 34 (1.14)               | 2976               |
|                     |         |              | 2976 (4.09)             | 194 (4.60)         |
| Grannis et al. (2021) [25] | USA     | Cohort study | 134 (2.94)              | 4551               |
|                     |         |              | 4551 (8.50)             | 1185 (20.76)       |
| Barlow et al. (2021) [6] | USA     | Case-control | 145 (29.00)             | 500                |
|                     |         |              | 500 (55.80)             | 279 (55.80)        |
| Hu et al. (2021) [29] | China   | Case-control | 187 (39.29)             | 476                |
|                     |         |              | 476 (38.66)             | 184 (38.66)        |
| Jara et al. (2021) [26] | Chile   | Cohort study | 12,286 (0.29)           | 4,173,574          |
|                     |         |              | 1,173,57 (3.39)         | 185,633 (3.39)     |
| Kislaya et al. (2021) [33] | Portugal | Case–control | 162 (11.89)             | 1363               |
|                     |         |              | 1363 (46.00)            | 777                |
| Li et al. (2021) [28] | China   | Case–control | 12 (12.37)              | 97                 |
|                     |         |              | 97 (34.58)              | 37 (34.58)         |
| Nanduri et al. (2021) [27] | USA     | Cohort study | 2999 (0.06)             | 5,011,746          |
|                     |         |              | 5,011,746 (0.15)        | 1,397 (0.15)       |
| Nasreen et al. (2021) [32] | Canada | Case–control | 10 (0.12)               | 8461               |
|                     |         |              | 8461 (22.03)            | 6325 (22.03)       |
| Tang et al. (2021) [31] | Qatar   | Case–control | 249 (0.02)              | 1,286,395          |
|                     |         |              | 1,286,395 (4.60)        | 4993 (4.60)        |
| Total, n = 12       |         |              | N = 16,361 (0.16)       | N = 10,514,132     |
|                     |         |              | N = 208,317 (3.12)      | N = 6,686,209      |
| Weighted pooled     |         |              | 8.88%                  | 21.61%             |
| incidence of        |         |              | (95% CI: 0.18–17.95)    | (95% CI: 8.50–34.72) |
| COVID-19 infection. |         |              | 8.88%                  | 21.61%             |

3.2. Effectiveness of the COVID-19 Vaccines against the Delta Variant

Figure 2 shows the effectiveness of the COVID-19 vaccines against the Delta variant after two doses. All four cohort studies showed that vaccines played a significant role in reducing the risk of COVID-19 infections among the fully vaccinated population, compared to the unvaccinated population. The pooling of four cohort studies [24–27] showed that vaccines significantly lowered the risk (RR = 0.20, 95% CI: 0.07–0.54) of exposure against the DV among the fully vaccinated (i.e., two-doses) population by 80% compared to the unvaccinated population. Pooled estimates for six case–control studies, except one study, showed a significantly lower risk of having COVID-19 infection (90%) (RR = 0.10, 95% CI: 0.01–0.80) against the delta variant in the fully vaccinated population than the unvaccinated population (Figure 2). Overall, the effectiveness of COVID-19 vaccines against the delta variant was 86% (RR = 0.14, 95% CI: 0.07–0.54). The funnel plot shows some asymmetry (Figure 3); however, this is not significant for Begg’s regression test (p = 481 for five case–control studies and p = 0.314 for five cohort studies) (Table 2), denoting an absence of publication bias. Therefore, we included all 11 studies in the meta-analysis. Our analysis suggests statistically significant heterogeneity (I² = 99.9%, p < 0.001 for six case–control studies and I² = 99.8%, p < 0.001 for four cohort studies, I² = 99.8%, p < 0.001) (Figure 2).
Weighted pooled incidence of COVID-19 infection. 8.88% (95% CI: 0.18 - 17.95) 21.61% (95% CI: 8.50 - 34.72)

Effectiveness of the COVID-19 Vaccines against the Delta Variant

Figure 2 shows the effectiveness of the COVID-19 vaccines against the Delta variant after two doses. All four cohort studies showed that vaccines played a significant role in reducing the risk of COVID-19 infections among the fully vaccinated population, compared to the unvaccinated population. The pooling of four cohort studies [24–27] showed that vaccines significantly lowered the risk (RR = 0.20, 95% CI: 0.07 – 0.54) of exposure against the Delta variant among the fully vaccinated (i.e., two-doses) population by 80% compared to the unvaccinated population. Pooled estimates for six case–control studies, except one study, showed a significantly lower risk of having COVID-19 infection (90% [RR = 0.10, 95% CI: 0.01 – 0.80] against the Delta variant in the fully vaccinated population than the unvaccinated population (Figure 2). Overall, the effectiveness of COVID-19 vaccines against the Delta variant was 86% (RR = 0.14, 95% CI: 0.07 – 0.54). The funnel plot shows some asymmetry (Figure 3); however, this is not significant for Begg’s regression test (p = 0.481 for five case–control studies and p = 0.314 for five cohort studies) (Table 2), denoting an absence of publication bias. Therefore, we included all 11 studies in the meta-analysis. Our analysis suggests statistically significant heterogeneity (I² = 99.9%, p < 0.001) for six case–control studies and I² = 99.8%, p < 0.001 for four cohort studies, I² = 99.8%, p < 0.001) (Figure 2).

Table 2. Assessing publication bias.

| Study Design       | Number of Studies | Egger’s Regression Test | Small-Study Effect |
|--------------------|-------------------|-------------------------|--------------------|
|                    |RR, (95% CI)       | p-Value                 | Bias (RR), 95% CI  |
|                    |                   |                         | p-Value            |
| Case-control       | 6                 | 0.61 (0.02, 5.53)       | 0.224              | 30.53 (0.89, 51.45) | 0.481 | p-value = 0.685 |
| Cohort study       | 4                 | 0.09 (0.04, 0.17)       | 0.015              | 13.32 (0.98, 45.47) | 0.390 | p-value = 0.390 |
| Case-case study    | 1                 | -                       | -                  | -                  | -     | -                |

RR = risk ratio, p-value = probability value.

Quality of Included Studies

Our findings suggest that five (n = 5) of the included studies [6,28–30,33] were of high quality, implying that they were robust studies; six of the studies [24,25,27,29,31,32] were ranked as medium quality, implying that their methods were of moderate quality based on the JBI quality assessment criteria. There was no study excluded based on poor scoring on the quality assessment scales. Notably, one (n = 1) cohort study [26] was assessed as high on the JBI tools; the rest (n = 3) cohort studies were found to be of medium quality on the same scale [24,25,27]. Three out of the six (n = 3/6) case–control studies included [6,28,30] were found to be of high quality based on the JBI quality assessment scale for case–control studies; the rest (n = 3) of the studies [29,31,32] were found to be of medium quality on the same scale (see Appendix A Tables A1–A3 for details). Lastly, the only case-series study [33]...
included in our review was found to be of high quality on the JBI quality assessment scale of case controls.

![Funnel plot with pseudo 95% confidence limits](image)

**Figure 3.** Assessing publication bias.

## 4. Discussion

In this catastrophic situation, several vaccines, including Pfizer-BioNTech, Moderna, and AstraZeneca, protect against SARS-CoV-2. These vaccines teach our cells how to make a protein (or even just a piece of a protein) that triggers an immune response inside our bodies. Theoretical benefits of these vaccines are that the vaccinated population will gain protection without ever having to risk the serious consequences of getting sick and dying of COVID-19. Several studies have confirmed that these vaccines trigger an immune response against the virus [26,37,38]. The vaccines have been approved for clinical use by the World Health Organization based on comprehensive assessments of non-clinical, laboratory confirmation, clinical utility, and manufacturing data provided by manufacturers to respective regulatory bodies (i.e., US Food and Drug Administration (FDA) and the Department of Health and Human Services or related institutes). Though these vaccines’ efficacy and side effects have not yet been widely discussed, numerous claims have been made by popular media and politicians [39,40]. During this process, respective government bodies examined the quality and consistency of the vaccine to determine if the potential benefits offset the potential adverse effects of the vaccine. Despite unsubstantiated claims on the COVID-19 vaccines’ efficacy and associated side effects, there is a lack of accumulated evidence on the effectiveness of this vaccine [26]. However, among different variants of SARS-CoV-2, the DV has a significantly increased virulence and transmission capacity [41]. In addition, recent evidence indicates that the vaccine’s effectiveness declined with the emergence and growth of the DV [6]. Therefore, this meta-analysis presents a piece of systematic and evidence-based information regarding the effectiveness of different COVID-19 vaccines against the specific DV.

The DV has seen a sharp rise in infections and mortality in 185 countries [2], including those with relatively high vaccine coverage and increased hospitalisation and mortality in the UK [20,42]. The high transmissibility of SARS-CoV-2, mainly of the DV, is a considerable...
socioeconomic global burden. Previous evidence on vaccine effectiveness reported reduced protection against the DV compared to the Alpha variant [1,30]. Even the efficacy of the two-dose ChAdOx1 vaccine decreased by 59.8% after exposure to B.1.617.2 [30]. Recent reports determined a higher vaccine breakthrough infection against the SARS-CoV-2 DV [1,30]. While more contributing factors may reduce immunity; a recent Israeli study has found higher infection rates even among the earliest vaccinated individuals [43]. Another study among nursing home residents found the effectiveness of the mRNA vaccine as 74.7% against infection, but the efficiency decreased significantly to 53.1% when the B.1.617.2 circulation predominated [27]. The interpretation of this finding is complex due to the bias of the methodology, research population, care settings, immunisation timeline and the potential selection and case diagnosis [6]. Our study found that the effectiveness of the COVID-19 vaccines was 80% more protective against the DV (RR = 0.20, 95% CI: 0.07–0.54) among those vaccinated compared to the unvaccinated population. A previous study also found a higher rate of infection, indicating the lower effectiveness of vaccines in protecting infection with the DV [33]. Another study also argued that infections with the DV that are transmitted despite the vaccine carry a similar viral burden for unvaccinated people [14]. Though the effectiveness of vaccines is lower among DV cases, completing the second dose of vaccines reduces the complication among those vaccinated [6]. In addition, a growing number of cases detected after one or two doses of vaccination are more likely to be infected with the DV than other variants [12]. Since the efficacy of the vaccines against the DV is lower, several studies have recommended an additional dose to curb the infection of the variant and optimise the immune response [12,27]. Single-dose vaccine recipients with high infection rates of DV or who have been infected before with another variant can risk vaccine-adapted forms of evolution [12]. We argue that the population should be vaccinated as much as possible since the unvaccinated cannot be protected by a significant reduction in the number of vaccinated people, as seen in other infections, making herd immunity unachievable due to emerging variants [14].

Our study is unique, with several strengths. Firstly, it is the first meta-analysis that provides evidence-based data on vaccines’ effectiveness against the DV. Secondly, we only considered studies that provide symmetrical information of individuals vaccinated with two doses. Thirdly, a large population was considered in this study, yielding adequate evidence on this topic. However, we acknowledge some limitations with our study design and selection of published studies. Effectiveness of vaccines (e.g., BNT162b2 or ChAdOx1 nCoV-19) after one dose was significantly lower among the population with the DV (30.7%) than among those with the Alpha variant (48.7%) [30]. Studies on single-dose vaccination and its efficacy were excluded in this meta-analysis due to the lack of reported data, lower effectiveness with the DV, and an insufficient number of studies, and we did not employ any analysis considering the sub-groups of different types of vaccines due to the insufficient number of studies that reported combined results with more than one vaccine.

Nonetheless, our study provides valuable insights into the effectiveness of the vaccines against the DV since there is a dearth of information on this topic. Depending on the predominance of the DV, the findings of this study may help policy-makers to act or undertake control measures and coordinate vaccination efforts. Recently, caution has been elevated that vaccine performance may diminish in the future, considering the possibility of a series of potential viral genetic drifts [6]. These claims highlight the importance of both pharmaceutical and non-pharmaceutical interventions in tandem in order to reduce SARS-CoV-2 infection. Future research could examine the combined efficacy of mass vaccination, contact tracing and social distancing measures in minimising the socioeconomic burden arising from COVID-19. Our study’s practical implication is that taking the mounting evidence on the efficacy of pharmaceutical intervention into account, mass vaccinations should be continued in a planned manner to lessen the socioeconomic burden of COVID-19. To do so, COVID-19 vaccines should be categorised as a global humanitarian good, emphasising the optimisation of production and equal distribution. On the other hand, the
demand side should target reducing vaccine hesitancy so that more vulnerable populations are adequately covered.

5. Conclusions

The effectiveness of COVID-19 vaccines was noted to offer higher protection against the Delta variant among populations after receiving two doses compared with unvaccinated populations. This finding would help efforts to maximise vaccine coverage (i.e., at least 60% to 70% of the population), with two doses among vulnerable populations, in order to create herd immunity, break the chain of transmission and gain greater overall population protection more rapidly.

Author Contributions: R.A.M. conceptualised the systematic review and meta-analysis. R.A.M., M.A.A., S.K. and M.A.R. conducted the search and data extraction under the supervision of A.M.N.R., R.A.M. performed the meta-analysis. All authors contributed to finalise the draft paper. R.A.M., M.A.A., S.K., M.A.R., J.K.K. and A.M.N.R. contributed to the revision and approval for submission. All authors have read and agreed to the published version of the manuscript.

Funding: No funding was received for conducting this study.

Institutional Review Board Statement: As the data were de-identified and came from publicly available published articles, this study did not require ethical approval.

Informed Consent Statement: Not applicable.

Data Availability Statement: The present study was a meta-analysis based on published original research articles. All data are publicly available within the manuscript. We have accessed the published articles. All statistical analyses were performed by STATA/SE version 15. The corresponding author can access a custom analysis codes (stata do-file).

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A

Table A1. Quality score assessment for cohort study.

| # | Quality Assessment Indicators | Fowlkes et al. (2021) [24] | Grannis et al. (2021) [25] | Jara et al. (2021) [26] | Nanduri et al. (2021) [27] |
|---|---------------------------|-----------------|-----------------|-----------------|-----------------|
| Q1 | Were the two groups similar and recruited from the same population? | ✓ | ✓ | ✓ | ✓ |
| Q2 | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | ✓ | ✓ | ✓ | ✓ |
| Q3 | Was the exposure measured in a valid and reliable way? | ✓ | ✓ | ✓ | ✓ |
| Q4 | Were confounding factors identified? | ✓ | ✓ | ✓ | ✓ |
| Q5 | Were strategies to deal with confounding factors stated? | ✓ | ✓ | ✓ | ✓ |
| Q6 | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | ✓ | ✓ | ✓ | ✓ |
| Q7 | Were the outcomes measured in a valid and reliable way? | ✓ | ✓ | ✓ | ✓ |
| Q8 | Was the follow-up time reported and sufficiently long enough for outcomes to occur? | ® | ® | ✓ | ® |
| Q9 | Was follow-up complete, and if not, were the reasons to loss to follow-up described and explored? | × | × | ® | × |
| Q10 | Were strategies to address incomplete follow-up utilised? | × | × | × | × |
| Q11 | Was appropriate statistical analysis used? | ✓ | ✓ | ✓ | ✓ |

Overall quality score 8.5 (medium) 8.5 (medium) 9.5 (high) 8.5 (medium)

Overall appraisal Included Included Included Included

Note: ✓ = yes (=1), X = no (=0), ® = unclear (=0.5); quality assessment decision rules for 11 scales [(i) poor if the overall score ≤ 5, (ii) medium if overall scores is 6 to 9, and (iii) high if the overall score > 9].
Table A2. Quality score assessment for case-control.

| #   | Quality Assessment Indicators                                                                 | Barlow et al. (2021) [6] | Li et al. (2021) [28] | Hu et al. (2021) [29] | Bernal et al. (2021) [30] | Tang et al. (2021) [31] | Nasreen et al. (2021) [32] |
|-----|-----------------------------------------------------------------------------------------------|--------------------------|-----------------------|------------------------|-------------------------|--------------------------|--------------------------|
| Q1  | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | ✓                        | ✓                     | ✓                      | ✓                       | ✓                        | ✓                        |
| Q2  | Were cases and controls matched appropriately?                                                  | ✓                        | ✓                     | ✓                      | ✓                       | ✓                        | ✓                        |
| Q3  | Were the same criteria used for the identification of cases and controls?                      | ✓                        | ✓                     | ✓                      | ✓                       | ✓                        | ✓                        |
| Q4  | Was exposure measured in a standard, valid and reliable way?                                   | ✓                        | ✓                     | ✓                      | ✓                       | ✓                        | ✓                        |
| Q5  | Was exposure measured in the same way for cases and controls?                                  | ✓                        | ✓                     | ✓                      | ✓                       | ✓                        | ✓                        |
| Q6  | Were confounding factors identified?                                                           | ✓                        | ✓                     | ✓                      | ✓                       | ✓                        | ✓                        |
| Q7  | Were strategies to deal with confounding factors stated?                                       | ✓                        | ×                     | ×                      | ✓                       | ✓                        | ✓                        |
| Q8  | Were outcomes assessed in a standard, valid and reliable way for cases and controls?          | ✓                        | ✓                     | ✓                      | ✓                       | ✓                        | ✓                        |
| Q9  | Was the exposure period of interest long enough to be meaningful?                               | ⚫                       | ×                     | ×                      | ×                       | ×                        | ⚫                        |
| Q10 | Was appropriate statistical analysis used?                                                      | ✓                        | ✓                     | ✓                      | ✓                       | ✓                        | ✓                        |
|     | Overall quality score                                                                         | 9.5 (high)               | 8 (high)              | 8 (medium)             | 9 (high)                | 8 (medium)               | 8 (medium)               |
|     | Overall appraisal                                                                             | Included                 | Included              | Included               | Included                | Included                 | Included                 |

Note: ✓ = yes (=1), X = no (=0), ⚫ = unclear (=0.5); quality assessment decision rules for 10 scales: (i) poor if the overall scores < 6, (ii) medium if the overall scores is 6 to 8, and (iii) high if the overall scores > 8.

Table A3. Quality score assessment for case-series study.

| #   | Quality Assessment Indicators for Case-Series Study | Kislaya et al. (2021) [33] |
|-----|-----------------------------------------------------|-----------------------------|
| Q1  | Were there clear criteria for inclusion in the case series? | ✓                           |
| Q2  | Was the condition measured in a standard, reliable way for all participants included in the case series? | ✓                           |
| Q3  | Were valid methods used for identification of the condition for all participants included in the case series? | ✓                           |
| Q4  | Did the case series have consecutive inclusion of participants? | ✓                           |
| Q5  | Did the case series have the complete inclusion of participants? | ⚫                           |
| Q6  | Was there clear reporting of the demographics of the participants in the study? | ✓                           |
| Q7  | Was there clear reporting of clinical information of the participants? | ✓                           |
| Q8  | Were the outcomes or follow-up results of cases clearly reported? | ✓                           |
| Q9  | Was there clear reporting of the presenting site(s)/clinic(s) demographic information? | ✓                           |
| Q10 | Was statistical analysis appropriate? | ✓                           |
|     | Overall quality score                             | 9.5 (high)                  |
|     | Overall appraisal                                 |                             |

Note: ✓ = yes (=1), X = no (=0), ⚫ = unclear (=0.5); quality assessment decision rules for 10 scales: (i) poor if the overall scores < 6, (ii) medium if the overall scores is 6 to 8, and (iii) high if the overall scores > 8.
References

1. Sheikh, A.; McMenamin, J.; Taylor, B.; Robertson, C. SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021, 397, 2461–2462. [CrossRef]

2. GISAID. Delta Variant Detected Across 185 Countries. Global Initiative on Sharing Avian Influenza Data (GISAID). Phylodynamics Pandemic Coronavirus Var. VOC Delta G/478K.V1 First Detect. India. 2021. Available online: https://www.gisaid.org/hcov19-variants/ (accessed on 30 September 2021).

3. Gallagher, J. COVID: Is There a Limit to How Much Worse Variants Can Get? How the R0 Numbers of COVID-19 Variants and Other Diseases Compare. 2021. Available online: https://www.bbc.com/news/health-57431420 (accessed on 30 September 2021).

4. Krause, P.R.; Fleming, T.R.; Petro, R.; Longini, I.M.; Figueroa, J.P.; Sterne, J.A.C.; Cravioto, A.; Rees, H.; Higgins, J.P.T.; Boutron, I.; et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet 2021, 6736, 21–24. [CrossRef]

5. Callaway, E. COVID vaccine boosters: The most important questions. Nature 2021, 596, 178–180. [CrossRef] [PubMed]

6. Barlow, R.S.; Jian, K.; Larson, L.; Barlow, R.S. Effectiveness of COVID-19 Vaccines Against SARS-CoV-2 Infection during a Delta Variant Epidemiemic Surge in Multnomah County, Oregon, July 2021. medRxiv 2021. [CrossRef]

7. Public Health England. Effectiveness of COVID-19 Vaccines against Hospital Admission with the Delta (B.1.617.2) Variant. 2021. Available online: https://khub.net/web/phe-national/public-library/-/document_library/v2Ws-%0ARK3ZIEig/view/47960726 (accessed on 12 August 2021).

8. Imai, N.; Hogan, A.B.; Williams, L.; Cori, A.; Mangal, T.D.; Winskill, P.; Whittles, L.K.; Watson, O.J.; Knock, E.S.; Baguelin, M.; et al. Interpreting estimates of coronavirus disease 2019 (COVID-19) vaccine efficacy and effectiveness to inform simulation studies of vaccine impact: A systematic review. Wellcome Open Res. 2021, 6, 185. [CrossRef]

9. Thompson, M.G.; Burgess, J.L.; Naleway, A.L.; Tyner, H.L.; Yoon, S.K.; Meece, J.; Olsho, L.E.W.; Caban-Martinez, A.J.; Fowlkes, A.; Lutrick, K.; et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among healthcare personnel, first responders, and other essential and frontline workers—eight US locations, December 2020–March 2021. Morb. Mortal. Wkly. Rep. 2021, 70, 495. [CrossRef]

10. Chemaitelly, H.; Yassine, H.M.; Benslimane, F.M.; Al Khatib, H.A.; Tang, P.; Hasan, M.R.; Malek, J.A.; Coyle, P.; Ayoub, H.H.; Al Kanaani, Z.; et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat. Med. 2021, 27, 1614–1621. [CrossRef]

11. Chung, H.; He, S.; Nasreem, S.; Sundaram, M.E.; Buchan, S.A.; Wilson, S.E.; Chen, B.; Calzavara, A.; Fell, D.B.; Austin, P.C.; et al. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada. BMJ 2021, 374, 1–12. [CrossRef]

12. Davis, C.; Logan, N.; Tyson, G.; Orton, R.; Harvey, W.; Haughney, J.; Perkins, J.; Peacock, T.P.; Barclay, W.S.; Cherepanov, P.; et al. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathog. 2021, 17, e1010022. [CrossRef]

13. Noori, M.; Nejadghaderi, S.A.; Arshi, S.; Carson-Chahhoud, K.; Ansarin, K.; Kolahi, A.A.; Safiri, S. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. Rev. Med. Virol. 2021, e2277. [CrossRef]

14. Pouwels, K.B.; Pritchard, E.; Matthews, P.C.; Stoesser, N.; Eyre, D.W.; Vihta, K.-D.; House, T.; Hay, J.; Bell, J.I.; Newton, J.N.; et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med. 2021, 27, 2127–2135. [CrossRef] [PubMed]

15. Chan, B.T.; Bobos, P.; Oudutyo, A.; Pai, M. Meta-Analysis of Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia Following ChAdOx1-S Recombinant Vaccine. medRxiv 2021. [CrossRef]

16. McDonald, I.; Murray, S.M.; Reynolds, C.J.; Altmann, D.M.; Boyton, R.J. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines 2021, 6, 74. [CrossRef] [PubMed]

17. Fogacci, F.; Ferri, N.; Toth, P.P.; Ruscio, M.; Corsini, A.; Cicero, A.F.G. Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines 2019, 7, 751–766. [CrossRef] [PubMed]

18. Hou, Z.; Tong, Y.; Du, F.; Lu, L.; Zhao, S.; Yu, K.; Pike, S.J.; Larson, H.J.; Lin, L. Assessing COVID-19 vaccine hesitancy, confidence, and public engagement: A global social listening study. J. Med. Internet Res. 2021, 23, e27632. [CrossRef]

19. Afolabi, A.A.; Ilesanmi, O.S. Dealing with vaccine hesitancy in Africa: The prospective COVID-19 vaccine context. Pan. Afr. Med. J. 2021, 38, 1–7. [CrossRef]

20. Public Health England. SARS-CoV-2 Variants of Concern and Variants under Investigation in England: Technical Briefing 18. Public Health England, Wellington House, 133–155 Waterloo Road, London SE1 8UG: 2021. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/990339/Variants_of_Concern_VOC_Technical_Briefing_13_England.pdf (accessed on 27 August 2021).

21. Mahmud, R.A.; Kamara, J.K.; Renzaho, A.M.N. The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: Evidence from a systematic review and meta-analysis. Infection 2020, 48, 813–833. [CrossRef]

22. Munn, Z.; McInStc, S.M.; Lisy, K.; Rittano, D.; Tufanaru, C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int. J. Evid. Based. Healthc. 2015, 13, 147–153. [CrossRef]

23. Joanna Briggs Institute (JBI). JBI’s Critical Appraisal Tools. Faculty of Health and Medical Sciences; The University of Adelaide: Adelaide, Australia. Available online: https://jbi.global/critical-appraisal-tools (accessed on 27 August 2021).
24. Fowlkes, A.; Gagliani, M.; Groover, K.; Thiese, M.S.; Tyner, H.; Ellingson, K. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance—Eight U.S. Locations, December 2020–August 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1167–1169. [CrossRef]

25. Grannis, S.J.; Rowley, E.A.; Ong, T.C.; Stenehjem, E.; Klein, N.P.; DeSilva, M.B.; Naleway, A.L.; Natarajan, K.; Thompson, M.G. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19—Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During B.1.617.2 (Delta) Variant Predominance—Nine States, June-August 2021. Morb. Mortal. Wkly. Rep. 2021, 70, 1291–1293. [CrossRef] [PubMed]

26. Jara, A.; Undurraga, E.A.; González, C.; Paredes, F.; Fontecilla, T.; Jara, G.; Pizarro, A.; Acevedo, J.; Leo, K.; Leon, F.; et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N. Engl. J. Med. 2021, 385, 875–884. [CrossRef] [PubMed]

27. Nanduri, S.; Pilishvili, T.; Derado, G.; Soe, M.M.; Dollard, P.; Wu, H.; Li, Q.; Bagchi, S.; Dubendris, H.; Link-Gelles, R.; et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant—National Healthcare Safety Network, March 1–August. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1163–1166. [CrossRef] [PubMed]

28. Li, X.-N.; Huang, Y.; Wang, W.; Jing, Q.; Zhang, C.; Qin, P.; Guan, W.; Gan, L.; Li, Y.; Liu, W.; et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant in China: A test-negative case-control real-world study. Emerg. Microbes Infect. 2021, 10, 1751–1759. [CrossRef] [PubMed]

29. Hu, Z.; Tao, B.; Li, Z.; Song, Y.; Yi, C.; Li, J.; Zhu, M.; Yi, Y.; Huang, P.; Wang, J. Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2.2 (Delta) variant-infected patients in Jiangsu, China. Int. J. Infect. Dis. 2021, 116, 204–209. [CrossRef]

30. Lopez Bernal, J.; Andrews, N.; Gower, C.; Gallagher, E.; Simmons, R.; Thelwall, S.; Stowe, J.; Tessier, E.; Groves, N.; Dabrera, G.; et al. Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 2021, 385, 585–594. [CrossRef]

31. Tang, P.; Hasan, M.R.; Chemaitelly, H.; Yassine, H.M.; Benslimane, F.M.; al Khatib, H.A.; AlMukdad, S.; Coyle, P.; Ayoub, H.H.; al Kanaani, Z.; et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar. Nat. Med. 2021, 27, 2136–2143. [CrossRef]

32. Nasreen, S.; He, S.; Chung, H.; Brown, K.A.; Gubbay, J.B.; Buchan, S.A.; Fell, D.B.; Austin, P.C.; Schwartz, K.L.; Sundaram, M.E.; et al. Effectiveness of COVID-19 vaccines against variants of concern, Canada. medRxiv 2021. [CrossRef]

33. Kislaya, I.; Rodrigues, E.F.; Borges, V.; Gomes, J.P.; Almeida, J.P.; Peralta-Santos, A.; Nunes, B. Delta variant and mRNA COVID-19 vaccines effectiveness: Higher odds of vaccine infection breakthroughs. medRxiv 2021. [CrossRef]

34. Higgins, J.P.T.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2001, 20, 3357–3483. [CrossRef] [PubMed]

35. Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [CrossRef]

36. Sterne, J.A.C.; Egger, M. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J. Clin. Epidemiol. 2001, 54, 1046–1055. [CrossRef]

37. Folegatti, P.; Ewer, K.J.; Aley, P.K.; Flaxman, A.L.; Folegatti, P.M.; Owens, D.R.; Voysey, M.; Aley, P.K.; Angus, B.; Babbage, G.; et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020, 396, 467–478. [CrossRef]

38. Xia, S.; Zhang, Y.; Wang, Y.; Wang, H.; Yang, Y.; Gao, G.F.; Tan, W.; Wu, G.; Xu, M.; Lou, Z.; et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet. Infect. Dis. 2021, 21, 39–51. [CrossRef]

39. Ison, M.G.; Wolfe, C.; Boucher, H.W. Emergency use authorization of remdesivir: The need for a transparent distribution process. JAMA 2020, 323, 2365–2366. [CrossRef]

40. US Food and Drug Administration. Emergency Use Authorization. 2020. Available online: https://www.fda.gov/ (accessed on 27 August 2021).

41. Burki, T.K. Lifting of COVID-19 restrictions in the UK and the Delta variant. Lancet Respir. Med. 2021, 9, e85. [CrossRef]

42. Sander, A.-L.; Yadouleton, A.; Moreira-Soto, A.; Tchiboza, C.; Tchiboza, C.; Hounkanrin, G.; Badou, Y.; Fischer, C.; Krause, N.; Akogbeto, P.; et al. An Observational Laboratory-Based Assessment of SARS-CoV-2 Molecular Diagnostics in Benin, Western Africa. MSphere 2021, 6, e00979-20. [CrossRef]

43. Mizrahi, B.; Lotan, R.; Kalkstein, N.; Peretz, A.; Perez, G.; Ben-Tov, A.; Chodick, G.; Gazit, S.; Patalon, T. Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine; Preliminary study. Nat Commun. 2021, 12, 6379. [CrossRef]